Last reviewed · How we verify
AGAR
AGAR is a marketed product that forms a gel-like matrix to support the growth of microorganisms, though its primary indication and revenue figures are not specified. A key strength is its unique mechanism of action, which provides a stable environment for microbial growth, potentially offering advantages in specific applications. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | AGAR |
|---|---|
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections
- Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study (NA)
- Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (PHASE1)
- Impact of BacT/Alert® VIRTUO®, BioFire® Blood Culture Identification 2-BCID2 and REVEAL® (bioMérieux) on the Optimization of Antibiotic Therapy for Gram-negative Bacteremia in the ICU (NA)
- Percutaneous Wound Sampling With Analysis in Blood Culture (PERKA-B) Method (NA)
- Effect of Agar/Collagen-based Compounds on Osteoarticular Pain: Randomized Triple-blind Clinical Trial (NA)
- Metagenomic Analysis of Bacterial Microbiota in Breast Milk
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |